Mineralys Therapeutics Q4 net loss narrows as R&D falls

Mineralys Therapeutics

12/03/2026 20:53

Overview

U.S. biopharma firm's Q4 net loss narrowed as R&D expenses declined after trial completion

FDA accepted NDA for lorundrostat in hypertension; PDUFA target date set for Dec 2026

Outlook

Mineralys expects FDA decision on lorundrostat NDA by December 22, 2026

Company expects current cash to fund operations and clinical activities into 2028

Result Drivers

R&D EXPENSE DECLINE - Co said lower R&D expenses were mainly due to the completion of the lorundrostat pivotal program in Q2 2025

HIGHER G&A COSTS - G&A expenses rose due to increased compensation, headcount, and professional fees

Cash, cash equivalents and investments were $656.6 million as of December 31, 2025, compared to $198.2 million as of December 31, 2024.

HIGHER INTEREST INCOME - Increase in other income was due to higher interest earned on investments from larger average cash balances

Company press release: ID:nGNX2LdfnF

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.40
Q4 Net Income
-$32.23 mln
Q4 Operating Expenses
$38.28 mln
Q4 Operating Income
-$38.28 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Mineralys Therapeutics Inc is $53.00, about 89.5% above its March 11 closing price of $27.97

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)